CDRxAbs: antibody small-molecule conjugates with computationally designed target-binding synergy.

Area of Science:

• Bioconjugation chemistry
• Computational protein design
• Molecular recognition

Background:

• Bioconjugates offer refined therapeutic action by combining molecular advantages.
• Current limitations exist in optimizing small molecule therapeutics for binding affinity and specificity.

Purpose of the Study:

• To introduce CDR-extended antibodies (CDRxAbs) as a new class of molecular recognition agents.
• To demonstrate the ability of CDRxAbs to improve small molecule binding affinity and specificity.

Main Methods:

• Utilized computational protein design with full atomic simulation.
• Integrated small molecules into antibody binding interfaces.
• Designed and optimized nanobody-biotin conjugates for proof-of-concept.

Main Results:

• Achieved >20-fold affinity improvement for nanobody-biotin conjugates against protein targets.
• Demonstrated step-wise optimization of binding kinetics and protein stability.
• Validated the CDRxAb concept in a proof-of-concept study.

Conclusions:

• CDRxAbs represent a novel approach to enhance small molecule-based therapeutics.
• This methodology promises to expand the chemical and target space for molecular recognition agents.
• CDRxAbs offer improved binding affinity and specificity compared to small molecules alone.